Teia Collier on MSN
Melissa McCarthy opens up about her weight loss and health journey
Melissa McCarthy recently stunned audiences while hosting Saturday Night Live, looking absolutely radiant in a fitted black ...
CNBC's Jim Cramer on Friday told investors what to look out for next week on Wall Street, including new economic data and earnings from FedEx and manufacturer Jabil.
9hon MSN
The score: Warner Bros., GameStop, Campbell’s, Lululemon and more stocks that defined the week
The athletic apparel company said Chief Executive Officer Calvin McDonald will step down in January and relinquish his board ...
MarketBeat on MSN
Why Zscaler stock could be ready to bounce after a 30% selloff
Shares of Zscaler Inc. (NASDAQ: ZS) have been going through a rough patch, sliding nearly 30% in just a few weeks and ...
NewsNation on MSN
Clinical trials reveal promising results for new Eli Lilly drug
The company announced Thursday that participants taking 12 milligrams of the drug lost an average of 71.2 lbs after 16 months ...
Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...
Fact checked by Vikki Velasquez Key Takeaways The Magnificent Seven make up roughly one-third of the S&P 500. If you own an index fund, you already have significant exposure.Market concentration isn't ...
TipRanks on MSN
Morning news wrap-up: Friday’s biggest stock market stories!
Investors seeking all of the latest and greats stock market stories for Friday will find them in our daily roundup.
Pfizer is still struggling to replace its COVID revenue. Here's what we could see from the pharmaceutical giant in 2026. Pfizer's coronavirus-related sales have fallen sharply -- and they may decline ...
Zacks Investment Research on MSN
Eli Lilly's next-generation obesity drug secures first phase III win
Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results